Skip to main content
All Posts By

admin

flc-award-nomination-logo

Submit Your 2018 FLC Awards Nominations Today!

By News Archive

flc-award-nomination-logo

The 2018 FLC Awards is now open for nominations. One of the most coveted honors in the technology transfer field, the FLC awards have been presented to over 200 federal laboratories since their inception in 1984. Many of our winning technology transfer efforts have gone on to become products and devices that are indispensable in our daily lives.

Read More
washington-view-3-pixa

Put Silicon Valley in D.C. With a Cyber Workforce Incubator – Lawfare

By News Archive

washington-view-3-pixa

DayZero: Cybersecurity Law and Policy It is no secret that Silicon Valley and Washington have dramatically different workplace cultures and attitudes toward risk and technology. In the valley, savvy entrepreneurs look to disrupt the status quo. Meanwhile in Washington, many of our elected representatives and government personnel are stuck decades in the digital past, forced to use equipment that would be better housed in a museum. This divide inhibits the country’s ability to respond effectively to long-standing problems such as vulnerable critical infrastructure and to adapt in light of new threats such as election interference operations and loss of advanced intelligence capabilities. Washington needs to boost its technical chops and find new ways to recruit private-sector talent.

Read More
Margaret-Anderson-deloitte-linkedin-image

Margaret Anderson Takes Managing Director Role at Deloitte Federal Health Practice

By News Archive

Margaret-Anderson-deloitte-linkedin-image

Margaret Anderson, formerly executive director at Washington-based FasterCures, has joined Deloitte Consulting LLP as a managing director for federal health practice.

Deloitte said Monday Anderson will oversee the firm’s health outcome improvement efforts through the advancement of platforms and collaboration with stakeholders across federal health, life sciences and nonprofit sectors.

Read More

271st Edition – September 19, 2017

By BHI Weekly Newsletter Archives

convergene-logo

ConverGene Announces Sponsored Research Agreement with MD Anderson

By News Archive

convergene-logo

ConverGene is pleased to announce that it has entered into a collaboration with The University of Texas MD Anderson Cancer Center (“MD Anderson”) to characterize ConverGene’s first-in-class dual inhibitor of BET bromodomains and dopamine receptor 2, in ovarian carcinoma.   Work will be done under the guidance of Dr. Sherry Wu in the laboratory of Dr. Anil Sood. The program will advance in 2 distinct phases. First the unique mechanism of action of the ConverGene lead compound will be assessed in vitro then clinically relevant activity will be determined utilizing in vivo model systems developed in the Sood lab.

Read More
montgomery-college-logo

Request for Proposal: Real Estate Consultant Services to Develop and Evaluate Developer Proposals

By News Archive

montgomery-college-logo

The Pinkney Innovation Complex for Science and Technology is located on the Montgomery College Germantown Campus. We’re also known as PIC MC. The College is ideally situated in Montgomery County, Maryland, within the Washington, DC metropolitan region.

The area is home to more than 350 bioscience companies and key federal institutions, including the National Institutes of Health, the Food and Drug Administration, the National Institute of Standards and Technology, and the Walter Reed Army Institute for Research.

Surrounded by woodlands, the site provides immediate access to the I-270 technology corridor. The park is currently being developed to accommodate life sciences, cybersecurity, and other technology companies.

Read More
Shuttle-Pharmaceuticals-logo

Shuttle Pharmaceuticals and POLA Pharma Inc. Agree to License U.S. Rights to Doranidazole

By News Archive

Shuttle-Pharmaceuticals-logo

Shuttle Pharmaceuticals, Inc. (USA) and POLA Pharma Inc. (Japan), today announced agreement to license the U.S. rights for doranidazole, a hypoxic cell radiation sensitizer, for clinical development in treating cancers in combination with stereotactic body radiation therapy (SBRT).  SBRT is used to deliver large doses of radiation in a few treatments with precise targeting of cancers. Current radiation dose limitations, due to sensitive normal tissues that may surround a tumor, support a role for radiation sensitizers to enhance the effectiveness of radiation. Clinical trials to determination safety and efficacy of the combination of doranidazole and SBRT are proposed for treating patients with pancreatic, lung and liver cancers.

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.